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Pathogenic significance of IgG and IgG.
antibodies against Candida albicans was
discussed in patients with bronchial asthma.
An increased production of IgG and IgG.
antibodies against Candida albicans has been
observed in patients with atopic between the
ages of 0 and 30, those with steroid-
dependent intractable asthma between 31 and
acterization of the mannose/fucose recep-
tor on human mononuclear phagocytes. J.
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40. Janusz MJ, Austen KF, et al. : Isolation
of yeast fJ - glucan that inhibit human
monocyte phagocytosis mediated by fJ-
glucan receptors. J. Immun. 137: 3270,
1986.
61, and elderly patients over the age of 61.
The mechanism of an increased production
of IgG and IgG. antibodies seems to be
related to atopy in patients between 0 and
30, long-term glucocorticoid therapy in those
with steroid-dependent intractable asthma
between 31 and 60, and aging in elderly
patients over age 61. Atopy, glucocorticoid
therapy and aging in general suppress cell-
mediated immunity, and suppressed cell-
mediated immunity increases growth of C.
albicans in patient's body, leading to an
increased production of IgG and IgG. anti-
bodies against C. albicans.
These results show that an increased pro-
duction of IgG and IgG. antibodies against
C. albicans is not always related to the
pathogenesis of bronchial asthma.
